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1.1 TUBERCULOSIS [
7, 8, 9, 11]
 
Tuberculosis (TB) is becoming a serious problem worldwide, and is responsible for at 
least three million deaths annually, as a life is lost to TB every 15 seconds. Factors 
involved in the resurgence of TB. Tuberculosis (TB) is a chronic bacterial infection, 
spread through the air, and caused by Mycobacterium tuberculosis (MTB) which is an 
aerobic bacilli belonging to the Mycobacteriaceae family. It was first identified in 
1882 by Robert Koch.  It mainly attacks lungs, although it can affect other organs as 
well.  
                          Fig.1                                                                                                                                                                                                                                                                                                                                    
 
NEED FOR FOCUS ON TUBERCULOSIS DISEASE: 
 Approximately 50% of the India’s population is reported to be tuberculin test positive 
 This led to the declaration of TB as a global emergency by WHO 1993. The 
regeneration of TB is closely linked to the emergence of HIV and total deficiency of 
the immune system. The WHO estimate is that up to 50 million persons worldwide 
are infected with drug resistant strains of TB.  On addition, 300,000 new cases of 
MDR-TB are diagnosed around the world each year and 79% of the MDR-TB cases 
now show resistance to three or more of the commonly used drugs. 
 More than 300,000 Indian children leave school every year, as they need to care for 
their parents who have TB .many end up getting it. 
 More than 100,000 Indian women suffering from TB are rejected by their families 
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 The HIV epidemic will increase tuberculosis cases by at least 200,000 each year in 
India, if HIV spreads more rapidly; tuberculosis may become uncontrollable for a 
generation. Despite enormous efforts, no new drug has been introduced in the market 
for the past 40 years. 
 The re-emergence of tuberculosis (TB) as a global health problem over the past few 
decades, accompanied by the rise of drug-resistant strains of Mycobacterium 
tuberculosis, emphasizes the need for discovery of new therapeutic drugs against this 
disease. 
 The emerging serious problem both in the terms of TB control and clinical 
management 
 Prompted us to search for new molecule as anti-tubercular agents. 
Patterns of Infection 
There are two major patterns of disease with TB: 
 Primary tuberculosis: seen as an initial infection, usually in children. The initial focus 
of infection is a small sub pleural granuloma accompanied by granulomatous hilar 
lymph node infection. Together, these make up the Ghon complex. In nearly all cases, 
these granulomas resolve and there is no further spread of the infection. 
 Secondary tuberculosis: seen mostly in adults as a reactivation of previous infection 
(or reinfection), particularly when health status declines. The granulomatous 
inflammation is much more florid and widespread. Typically, the upper lung lobes are 
most affected, and cavitation can occur. 
When resistance to infection is particularly poor, a "miliary" pattern of spread can 
occur in which there are a myriad of small millet seed (1-3 mm) sized granulomas, 
either in lung or in other organs. 
Dissemination of tuberculosis outside of lungs can lead to the appearance of a number 
of uncommon findings with characteristic patterns: 
Skeletal Tuberculosis: Tuberculosis osteomyelitis involves mainly the thoracic and 
lumbar vertebrae (known as Pott's disease) followed by knee and hip. There is 
extensive necrosis and bony destruction with compressed fractures (with kyphosis) 
and extension to soft tissues, including psoas "cold" abscess. 
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Genital Tract Tuberculosis: Tuberculosis salpingitis and endometritis result from 
dissemination of tuberculosis to the fallopian tube that leads to granulomatous 
salpingitis, which can drain into the endometrial cavity and cause a granulomatous 
endometritis with irregular menstrual bleeding and infertility. In the male, 
tuberculosis involves prostate and epididymis most often with non-tender induration 
and infertility. 
Urinary Tract Tuberculosis: A "sterile pyuria" with WBC's present in urine but a 
negative routine bacterial culture may suggest the diagnosis of renal tuberculosis. 
Progressive destruction of renal parenchyma occurs if not treated. Drainage to the 
ureters can lead to inflammation with ureteral stricture. 
CNS Tuberculosis: A meningeal pattern of spread can occur, and the cerebrospinal 
fluid typically shows a high protein, low glucose, and lymphocytosis. The base of the 
brain is often involved, so that various cranial nerve signs may be present. Rarely, a 
solitary granuloma, or "tuberculoma", may form and manifest with seizures. 
Gastrointestinal Tuberculosis: This is uncommon today because routine 
pasteurization of milk has eliminated Mycobacterium bovis infections. However, M. 
tuberculosis organisms coughed up in sputum may be swallowed into the GI tract. 
The classic lesions are circumferential ulcerations with stricture of the small intestine. 
There is a predilection for ileocecal involvement because of the abundant lymphoid 
tissue and slower rate of passage of luminal contents. 
Adrenal Tuberculosis: Spread of tuberculosis to adrenals is usually bilateral, so that 
both adrenals are markedly enlarged. Destruction of cortex leads to Addison's disease. 
Scrofula: Tuberculosis lymphadenitis of the cervical nodes may produce a mass of 
firm, matted nodes just under the mandible. There can be chronic draining fistulous 
tracts to overlying skin. This complication may appear in children, and 
Mycobacterium scrofulaceum may be cultured. 
Cardiac Tuberculosis: The pericardium is the usual site for tuberculosis infection of 
heart. The result is a granulomatous pericarditis that can be haemorrhagic. If extensive 
and chronic, there can be fibrosis with calcification, leading to a constrictive 
pericarditis. 
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The following images illustrate gross pathologic findings with tuberculosis: 
Microscopic Findings 
Microscopically, the inflammation produced with TB infection is granulomatous, with 
epithelioid macrophages and Langhans giant cells along with lymphocytes, plasma 
cells, maybe a few PMN's, fibroblasts with collagen, and characteristic gaseous 
necrosis in the center. The inflammatory response is mediated by a type IV 
hypersensitivity reaction. This can be utilized as a basis for diagnosis by a TB skin 
test. An acid fast stain (Ziehl-Neelsen or Kinyoun's acid fast stains) will show the 
organisms as slender red rods. An auramine stain of the organisms as viewed under 
fluorescence microscopy will be easier to screen and more organisms will be 
apparent. The most common specimen screened is sputum, but the histologic stains 
can also be performed on tissues or other body fluids. Culture of sputum or tissues or 
other body fluids can be done to determine drug sensitivities. 
Tuberculin Skin Testing 
Skin testing for tuberculosis is useful in countries where the incidence of tuberculosis 
is low, and the health care system works well to detect and treat new cases. In 
countries where BCG vaccination has been widely used, the TB skin test is not useful, 
because persons vaccinated with BCG will have a positive skin test. 
The TB skin test is based upon the type 4 hypersensitivity reaction. If a previous TB 
infection has occurred, then there are sensitized lymphocytes that can react to another 
encounter with antigens from TB organisms. For the TB skin test, a measured amount 
(the intermediate strength of 5 tuberculin units, used in North America) of tuberculin 
purified protein derivative (PPD) is injected intracutaneously to form a small wheal, 
typically on the forearm. In 48 to 72 hours, a positive reaction is marked by an area of 
red induration that can be measured by gentle palpation (redness from itching and 
scratching doesn't count). Reactions over 10 mm in size are considered positive in 
non-immunocompromised persons. 
Repeated testing may increase the size of the reaction (induration), but repeated TB 
skin testing will not lead to a positive test in a person not infected by TB. Anergy, or 
absence of PPD reactivity in persons infected with TB, can occur in 
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immunocompromised persons, or it may even occur in persons newly infected with 
TB, or in persons with miliary TB. 
1.2. MEDICINAL CHEMISTRY 
Medicinal chemistry is a discipiline at the intersection of chemistry and pharmacology 
and involves the drug discovery process. 
The drug discovery process involves designing, synthesizing, characterization and 
evaluation of new chemical entities, suitable for therapeutic use.it also includes the 
study of existing drugs, their biological properties, and their quantitative structure 
activity relationship (QSAR) 
PROCESS IN DRUG DISCOVERY 
DISCOVERY 
[23]
 
Discovery is the identification of novel active compounds, often called “hits”, which 
are typically found by screening many compounds (compound library) for the desired 
biological properties. While a number of approaches toward the identification of hits 
exist, the most successful of techniques relies on chemical and biological intuition 
developed through years of rigorous chemical –biological training. Other sources of 
hits can come from natural sources, such as plants, animals, or fungi. Hits may 
originate also from synthetic chemical libraries, such as those created through 
combinatorial chemistry or historic chemical compound collections that are tested 
enmasse against the biological target in question. 
 
OPTIMIZATION: 
Another step in drug discovery involves further chemical modifications in order to 
improve the biological and physiochemical properties of a given candidate compound 
library. Chemical modifications can improve the recognition and binding geometries 
(Pharmacophore) of the candidate compounds, their affinities and pharmacokinetics, 
or indeed their reactivity and stability during their metabolic degradation .which 
exhibit the most potency, most selectivity, best pharmacokinetics and least toxicity. 
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QSAR involves mainly physical, chemistry and molecular docking tools (COMFA 
and COMSIA), that leads to tabulated data and first and second order equations. 
There are many theories, the most relevant being Hansch, analysis that involves 
Hammett electronic parameters, steric parameters and logP (lipophilicity) parameters. 
1.3. DRUG DESIGN 
[5 ] 
 
Drug design, also sometimes referred to as rational drug design, is the inventive 
process of finding new medications based on the knowledge of the biological target. 
The drug is most commonly an organic small molecule which activates or inhibits the 
function of a biomolecule such as a protein, which in turn results in a therapeutic 
benefit to the 
patient
. In the most basic sense, drug design involves design of small 
molecules that are complementary in shape and charge to the biomolecular target to 
which they interact and therefore will bind to it. Drug design frequently but not 
necessarily relies on computer modelling techniques. This type of modelling is often 
referred to as computer-aided drug design (CADD). 
1.3.1 TYPES 
There are two major types of drug design. The first is referred to as ligand based drug 
design and the second, structure-based drug design. 
LIGAND BASED 
Ligand –based drug design (or indirect drug design) relies on knowledge of other 
molecules that bind to the biological target of interest. These other molecules may be 
used to derive a Pharmacophore model which defines the minimum necessary 
structural characteristics a molecule must possess in order to bind to the target.in other 
words, a model of the biological target may be build based on the knowledge of what 
binds to it and this model in turn may be used to design new molecular entities that 
interact with the target. Alternatively , a quantitative  structure –activity relationship 
(QSAR) in  which a correlation  between calculate properties of molecules and their 
experimentally determined biological activity may be derived .these QSAR 
relationships in turn may be used to predict the  activity  of new analogues. 
STRUCTURE BASED:  Structure - based drug design (or direct drug design) relies 
on knowledge of the three dimensional structure of the biological target obtained 
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through methods such as x –ray crystallography or NMR spectroscopy. If an 
experimental structure of a target is not available, it may be possible to create a 
homology model of the target based on the experimental structure of a related protein. 
Using the structure of the biological target, candidate drugs that are predicted to bind 
with high affinity and selectivity to the target may be designed using interactive 
graphics and the intuition of a medicinal chemist. Alternatively various automated 
computational procedures may be used to suggest new drug candidates 
1.3.2 PRESENT AND FUTURE 
Today, computer-aided drug design and screening methods impacts the efforts impact 
the efforts of all pharmaceutical companies.as the computational technologies 
advance, the role they play in improving the efficiency of the drug discovery process 
will become increasingly important. In addition, as the body of structural information 
on potential therapeutic targets dramatically expands, which is expected to happen in 
the next few years, it will drive the development of the computational methodology. 
Greater automation, faster algorithms and improved information management 
techniques will be required to handle sheer volume of target related information that 
will need to be processed. On a genomic scale, instead of looking at individual 
targets, families of related targets will be studied. The information available on ligand 
binding to these families will be vastly expanded. The job of the molecular modeller 
will be to effectively mine this data as well as translate the available structural 
information into a form directly usable by the bench chemist. This mission will 
ultimately cause a greater interface of bio and chemo informatics, leading to improved 
structural and functional genomics knowledge. 
1.3.3 DOCKING
 [21]
 
Docking is frequently used to predict the binding orientation of small molecule drug 
candidates to their protein targets in order to in turn predict the affinity and activity of 
small molecule. Hence docking plays an important role in the rotational design of 
drugs. Given the biological and pharmaceutical significance of molecular docking, 
considerable efforts have been directed towards improving the methods used to 
predict docking. The quality of any docking results depends on reasonable starting 
structures for both the protein and the ligand. The protein and the ligand structures 
need to be preparing to achieve the best docking results. 
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PROTEIN PREPARATION: 
A typical PDB (protein data bank) structure file consists of heavy atoms and contains 
water, cofactors, and metal ions and can be multimeric. The structure generally has 
information on bond orders, topologies, or formal atomic charges. Terminal amide 
groups can also be misaligned, because the x-ray structure analysis cannot usually 
between O and NH2.Ionisation and tautomeric states are generally unassigned. 
The following processes are necessary to make protein to perfect structure for docking 
study: 
1. Assign ionisation and tautomer states of protein properly. (Side chains are 
reoriented when necessary and steric clashes are relieved.) 
2. Delete all water molecules (except those coordinated to metals, if water molecules 
are kept, hydrogens will be added to them.) 
3. Adjust the protonation of the protein, which is crucial when the receptor site is 
metalloproteinase 
4. Finally minimize the protein to reorient side chain hydroxyl groups and alleviate 
potential steric clashes present in the PDB structure. 
 
LIGAND PREPARATION 
To give the best results, the structures that are docked must be good representations of 
the   actual ligand structures as they would appear in a protein –ligand complex. Most 
of the docking tools only modify the torsional internal coordinates of the ligand 
during docking, so the rest of the geometric parameters must be optimized 
beforehand. This means that the structures supplied to docking tool must meet the 
following conditions: 
 They must be three-dimensional (3d) 
 They must have realistic bond lengths and bond angles 
 They must each consist of a single molecule that has no covalent bonds to the 
receptor, with no accompanying fragments, such as counter ions and solvent 
molecules 
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 They must have all their hydrogens (filled valences) 
 They must have an appropriate protonation state for physiological pH values 
ABSORPTION, DISTRIBUTION, METABOLISM, EXCRETION (ADME) 
ANALYSIS 
[29]
 
DRUG DISCOVERY and development are expensive and time –consuming 
processes. Recognition by the pharmaceutical industry that undesirable absorption 
,distribution, metabolism and excretion(ADME) properties of new drug candidates are 
the cause of many clinical phase drug development failures has resulted in a paradigm 
shift to identify such problems early in the drug discovery process. Thus in vitro 
approaches are now widely used to investigate the ADME properties of new chemical 
entities and more recently, computational (in silico) modelling has been investigated 
as a tool to optimise selection of the most suitable drug candidates for development. 
The objective of in silico modelling tools is for predicting these properties to serve 
aim key aims. First, at the design stage of new compounds and compound libraries so 
as to reduce  the risk of  late –stage attrition; and second , to  optimize  the screening 
and testing by looking at only the most promising compounds. 
Drug like properties 
The properties which can differentiate drugs from other chemicals can be considered 
as a drug like properties. The  crucial properties that should be considered for 
compounds with oral delivery (Lipinski’s rule - of  - five) includes molecular mass 
<500 Daltons(Da), calculated octanol/water  partition coefficient(CLOGP)<5 number 
of hydrogen –bond donors<5 and number of hydrogen bond  acceptors<10. These 
properties are than typically used to construct predictive ADME models and form the 
basis for what has been called property-based design. 
A deeper understanding of the relationships between important ADME parameters 
and molecular structure and   properties has been used to develop in silico models that 
allow the early estimation of several ADME properties. Among other important 
issues, prediction of properties that provide information about dose size and dose 
frequency such as oral absorption, bioavailability, brain penetration, clearance (for 
exposure) and volume of distribution (for frequency) also needed. 
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Prediction of ADME and related properties
 [45]
 
Absorption  
For a compound crossing a membrane by purely passive diffusion, a reasonable 
permeability estimate can be made using single molecular properties, such as log D 
(diffusion co efficient) or hydrogen –bonding capacity.  The simplest Insilco models 
for estimating absorption are based on a single descriptor, Such as logP (partition 
coefficient) or log D, or polar surface area, which is a descriptor of hydrogen-bonding 
potential. Different multivariate approaches such as multiple liner regressions, partial 
least squares and artificial neural networks, have been used to develop quantitative 
structure-human-intestinal-absorption relationships. 
Bioavailability 
Important properties for determining permeability seem to be the size of the molecule, 
as well as its capacity to make hydrogen bonds, its overall lipophilicity and possibly 
its shape and flexibility. 
Blood –Brain Barrier penetration (BBB) 
Drugs that act in the CNS need to cross the blood –brain barrier (BBB) to reach their 
molecular target.by contrast, for drugs with a peripheral target, little or no BBB 
penetration might be required in order to avoid CNS side effects. Rule –of –five like 
recommendations regarding the molecular parameters that contribute to the ability of 
molecules to cross the BBB have been made to aid BBB-penetration predictions; for 
example molecules with a molecular mass of <450Da or with polar surface area 
(PSA) <100A0 are more likely to penetrate the BBB. 
Dermal and ocular penetration 
The existing transdermal models are typically a function of the octanol/water partition 
coefficient and dermas that have been associated with aqueous solubility, including 
hydrogen – bonding parameters, molecular weight and molecular flexibility. 
Commercial models for the prediction of solute –permeation rates through the skin are 
available, for example Qikrop and DermWin programs. 
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METABOLISM  
In silico approaches to predicting metabolism can be divided into QSAR and three –
dimensional-QSAR studies, protein and Pharmacophore models and predictive 
databases. Some of the first –generation predictive –metabolism tools currently 
require considerable input from a computational chemist, whereas others can be used 
as rapid filters for the screening of virtual libraries. Perhaps the most intellectually 
satisfying molecular modeming studies are those based on the crystal structure of the 
metabolizing enzymes. Several approaches that use databases to predict metabolism 
are available. Ultimately, such programs might be linked to computer-aided toxicity 
prediction on the basis of quantitative structure-toxicity relationships and expert 
systems for toxicity evaluation. 
In silico PREDICTION OF TOXICITY ISSUES   
Toxicity is responsible for many compounds failing to reach the market and for the 
withdrawal of a significant number of compounds from the market once they have 
been approved. It has been estimated that -20-40% of drug failures in investigational 
drug development can be attributed to toxicity concerns. The existing commercially 
available in silico tools for forecasting potential toxicity issues can be roughly 
classified into two groups. The first approach uses expert systems that derive models 
on the basis of abstracting and codifying knowledge from human experts and the 
scientific literature. The second approach relies primarily on the generation of 
descriptors of chemical structure and statistical analysis of the relationships between 
these descriptors and the toxicological end –point. 
The primary emphasis of the current software packages is carcinogenicity and 
mutagenicity, although some packages do also include models and /or knowledge 
bases for other end –points, such as teratogenicity, irritation, sensitization, 
immunotoxicology and neurotoxicity .there is currently an unmet need for in silico 
predictive toxicology software for other end –points important in drug development, 
such as QT prolongation hepatotoxicity and phospholipidosis. 
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BINDING SITE ANALYSIS 
Understanding the structure and function of protein binding sites is the cornerstone of 
structure –based drug design .developing this understanding requires knowledge of 
both the location and physical properties of the binding site .in addition ,the 
identification of small –molecule  binding sites  as modulators of protein-protein 
interactions is of increasing interest furthermore, even when a validated binding site 
has been identified ,it is often important to find additional potential binding sites 
where appropriate targeting could result in different biological effects or new classes 
of compounds .when  the binding site is not known from a 3-D structure or from other 
experimental data, computational methods  can be employed to  suggest likely 
locations. When the location of the primary binding site is known, medicinal 
chemistry efforts to  design better ligands can profit from a better understanding  of 
the degree to which known ligands are ,or fail to be ,complementary to the receptor as 
well as from a critical assessment of the degree  to  which the occupancy of accessible 
but unexplored regions by appropriate ligand functionality  can  be expected to 
promote  binding or could be used to improve the physical properties of the ligand  
without lessening its binding affinity. Such assessments can assist in the evaluation 
and optimization both of known binding molecules and of virtual screening hits.it is 
also important to understand the potential drugs ability of the site. 
SCORING METHODS 
Scoring of docked poses is still regarded as one of the major challenges in the field of 
molecular docking. The purpose of the scoring procedure is the identification of the 
correct binding pose by its lowest energy value, and the ranking of protein –ligand 
complexes according to their binding affinities. Scoring functions can be divided in 
empirical scoring functions, scoring functions derived from force fields, and 
knowledge –based scoring functions. Scoring functions derived from force fields 
handle the ligand binding prediction with the use of potential energies (non –bonded 
interaction terms) and sometimes in combination with solvation’s and entropy 
contributions knowledge- based scoring functions are based on atom pair potentials 
derived from structural databases forces and potentials are collected from known 
protein –ligand complexes to get a       score    for their    binding affinities. 
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1.4 ENZYME PROFILE 
[30]
 
MmaA2 is required for introduction of the distal cyclopropane ring in the formation of 
meroacids. Analysis of a mmaA2 deletion mutant of M. tuberculosis revealed that _-
mycolic acid lacks a distal cyclopropane group and instead contains a cis 
unsaturation. Thus, mmaA2 is required for the distal cyclopropane modification of _-
mycolic acid 
 
Functional category: lipid metabolism  
 
Targeting Cell Wall Synthesis 
[36
, 39
] 
Mycolic acids, which are key components of the mycobacterial cell wall, are alpha-
alkyl, beta-hydroxy fatty acids, with a species-dependent saturated "short" arm of 20-
26 carbon atoms and a "long" mero mycolic acid arm of 50-60 carbon atoms. The 
latter arm is functionalized at regular intervals by cyclopropyl, alpha-methyl ketone, 
or alpha-methyl methyl ethers groups. The mycolic acid biosynthetic pathway has 
been proposed to involve five distinct stages: (i) synthesis of C20 to C26 straight-
chain saturated fatty acids to provide the alpha-alkyl branch; (ii) synthesis of the mero 
mycolic acid chain to provide the main carbon backbone, (iii) modification of this 
backbone to introduce other functional groups; (iv) the final Claisen-type 
condensation step followed by reduction; and (v) various mycolyltransferase 
processes to cellular lipids. The drugs shown to inhibit mycolic acid biosynthesis are 
isoniazid, ethionamide, isoxyl, thiolactomycin, and triclosan. In addition, 
pyrazinamide was shown to inhibit fatty acid synthase type I which, in turn, provides 
precursors for fatty acid elongation to long-chain mycolic acids by fatty acid synthase 
II. 
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Structures of Mycolic Acid Cyclopropane Synthases
 [2, 3, 21] 
Fig.2 
 
 
Mycolates contain cyclopropane rings at both the distal and the proximal positions. 
Methoxymycolates and ketomycolates have cis or Tran’s cyclopropane rings at the 
proximal position and the oxygenated functional group at the distal position.   (i) The 
cyclopropane rings of mycolic acids in M. tuberculosis contribute to the structural 
integrity of the cell wall complex. Moreover, the cyclopropane rings protect the 
bacillus from oxidative stress. Thus, the structure of mycolic acids determines the 
degree of protection that M. tuberculosis receives against the hostile   environment of 
the host. (ii) Deletion of the proximal cyclopropane ring of mycolate or deletion of the 
methoxy- and keto-mycolates leads to a significant attenuation of growth of the two 
mutants in the mouse model of infection. Deletion of keto-mycolates in 
M.tuberculosis leads to restricted growth of this mutant in macrophages. Thus, the 
distribution and fine structure of mycolic acids determine the virulence of M 
tuberculosis. It can be concluded that mycolic acids are very important components of 
the pathogenic M. tuberculosis. (iii) Mycolic acid synthesis is the target of well-
known antituberculosis drugs, i.e., isoniazid, ethionamide, and thiocarlide. This 
suggests that all reactions on the pathway to synthesis and processing of mycolic 
acids are viable targets for new drug discovery (target validation) and to find new and 
more effective drugs against multiple-drug-resistant strains of M. tuberculosis. 
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The cell wall contains a very high proportion of lipid in the form of mycolic acid. 
Mycolic acids are long-chain, two-branched, 3-hydroxy fatty acids that range in size 
in mycobacteria from '60 to 80 carbons and contain a variety of functional groups on 
the long (mero) chain . These functional groups are either nonpolar moieties, such as 
olefins, methyl branches, and Cyclopropane, or polar moieties, such as ketones, 
methoxy groups, epoxides, and esters. The distribution of functional groups among 
species is distinct and useful for taxonomic identification of species. In M. 
tuberculosis, three distinct mycolate species are produced, a mycolates containing two 
cis-cyclopropane rings and a methoxy and keto series, each of which contains a cis- or 
trans-cyclopropane in the proximal position, in addition to the distal oxygen function 
with an adjacent methyl branch. In M. tuberculosis and related organisms, methoxy- 
and ketomycolates are generally of lower abundance than a mycolates, although the 
exact ratios are dependent upon growth conditions.  
    Fig.3 
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Methyltransferases and oxidation-reduction (redox) to form the methoxy group of 
methoxy-meroacids and the Oxo group of keto-meroacids on the pathway to synthesis 
of oxygenated meroacids. MmaA2 introduces the methyl group on the secondary 
alcohol, MmaA3   introduces the proximal cis-cyclopropane ring, and CmaA2 
introduces the proximal trans-cyclopropane ring. Redox is the proposed   oxidation-
reduction system that converts the secondary alcohol to an Oxo group. T and c, Trans 
and cis isomers, respectively.                
The Field of Heterocyclic Chemistry 
For centuries ago, heterocyclic have contributed their presence in the field of research 
and development in organic chemistry.as a result, millions of heterocyclic compounds 
found to exist, synthesized having special properties with biological importance. 
Recently, analysis of organic compounds as of June 2007, there were 24,282,284, 
compounds were registered in chemical abstracts containing cyclic structures with 
heterocyclic systems making up of many compounds. Among various heterocyclic 
compounds, we have chosen pyridine based compound namely, acridine. 
ACRIDINE 
Acridine is structurally related to anthracene with one of the central CH groups is 
replaced by nitrogen. Acridine, a colourless solid, was first isolated from coal tar. It is 
a raw material used for the production of dyes and some valuable drugs. Many 
acridines, such as proflavine, also have antiseptic properties. Acridine and related 
derivatives bind to DNA and RNA due to their abilities to intercalate. Acridine 
orange (3,6-dimethylaminoacridine)is anucleicacid-selective etachromatic stain useful 
for cell cycle determination. Acridarsine is formally derived from acridine by 
replacing the nitrogen atom with one of arsenic, and acridophosphine by replacing it 
with one of phosphorus. 
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 1.5 SCHIFF BASE 
[1, 16, 26] 
Schiff bases are condensation products of primary amines with carbonyl compounds 
and they were first reported by Schiff in 1864. The common structural feature of these 
compounds is the azomethine group with a general formula RHC=N-R1, where R and 
R1 are alkyl, aryl, cyclo alkyl or heterocyclic groups which may be variously 
substituted. These compounds are also known as anils, imines or azomethines. Several 
studies showed that the presence of a lone pair of electrons in a sp2 hybridized orbital 
of nitrogen atom of the azomethine group is of considerable chemical and biological 
importance. Because of the relative easiness of preparation, synthetic flexibility, and 
the special property of C=N group, Schiff bases are generally excellent chelating 
agents, especially when a functional group like –OH or –SH is present close to the 
azomethine group so as to form a five or six membered ring with the metal ion. 
Versatility of Schiff base ligands and biological, analytical and industrial applications 
of their complexes make further investigations in this area highly desirable. 
Schiff bases have been known since 1864 when Hugo Schiff reported the 
condensation of primary Amines with carbonyl compounds. Nowadays, the research 
field dealing with Schiff base coordination chemistry has expanded enormously. The 
importance of Schiff base complexes for bioinorganic chemistry,  biomedical 
applications, supramolecular chemistry, catalysis and material science, separation and 
encapsulation processes, and formation of compounds with unusual properties and 
structures has been well recognized and reviewed. 
                                 
Reaction Mechanism 
 
 
Schiff bases are synthesized from an aromatic amine and a carbonyl compound by 
nucleophilic addition forming a hemiaminal, followed by a dehydration to generate 
imines. 
Fig.4 
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LITERATURE REVIEW 
Literature review on Tuberculosis research 
 Williams, B.G et al., (2010) studied about the “The Population Dynamics and 
Control of Tuberculosis.” 
 
 De Souza MVN, et al., (2006) Current status and future prospects for new 
therapies for pulmonary tuberculosis. 
 
 Duncan K, et al., (2004) Prospects for new antitubercular drugs. 
 
 Cohn, D. L et al., (1997) reported a “Drug-resistant tuberculosis: review of 
the worldwide situation and the WHO/IUATLD global surveillance project 
 Glickman SW et al., (2006) A Portfolio model of drug development for 
tuberculosis. 
 
Literature review on Target of interest- Alpha methoxy Mycolic acid inhibitor  
 Asselineau.J et al., (1950) reported “Structure of the mycolic acids of 
mycobacteria’’ 
 Barry.C.E., et al., ( 1998) reported “Mycolic acids: structure, biosynthesis 
and physiological functions.                     
 Ying Yuan et al., (1996) reported “A common mechanism for the 
biosynthesis of methoxy and cyclopropyl mycolic acids in Mycobacterium 
tuberculosis. 
 Santos.DS et al., (2002) reported the Drugs that inhibit mycolic acid 
biosynthesis in Mycobacterium tuberculosis. 
 Michael S. Glickman et al., (2002)   Acid cyclopropane synthase of the alpha 
mycolic tuberculosis encodes the distal the mmaA2 gene of Mycobacterium 
 Gurdyal S. Besra et al.,( 2005,) studied  a   ‘’  Pathway to Synthesis and 
Processing of Mycolic Acids in Mycobacterium tuberculosis’  
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Literature review on drug design  
 Guner Osman.F (2000) reported a Pharmacophore Perception, Development, 
and use in Drug Design. 
 Schnecke,V et al.,.(2000)  wrote a book on Perfect Drug Discov. 
 Lipinski CA et al., (2001) reported a "Experimental and computational 
approaches to estimate solubility and permeability in drug discovery and 
development settings". 
 Oprea TI (2001) wrote a book on “Is there a difference between leads and 
drugs? A historical perspective".  
 Tarbit MH.et al., (2002) reported “The emerging importance of predictive 
ADME simulation in drug discovery’’ 
 Madsen et al., (2002) wrote a book on Textbook of Drug Design and 
Discovery. 
 Kitchen DB, et al., (2004) reported a "Docking and scoring in virtual 
screening for drug discovery: methods and applications". 
 Lipinski CA (2004) reported a "Lead- and drug-like compounds: the rule-of-
five revolution".     
 P. LALITHA et al.,(2010) reported a Calculation of molecular lipophilicity 
and drug likeness for few heterocycles. 
 
 Cohen.NClaude (1996) wrote a book on Guidebook on Molecular Modelling 
in Drug Design. 
Literature review on Biological screening 
 Scott G.Franzblau et al., (1998) studied the Rapid, Low-Technology MIC 
Determination with Clinical Mycobacterium tuberculosis Isolates by Using the 
Microplate Alamar Blue Assay. 
 
 Bornman, D.L et al., (2001) reported an Assessment of a simple, non –toxic 
Alamar Blue cell survival assay to monitor tomato cell viability.  
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 Maria C. S. et al., (2007) reported an Evaluation of anti-Tubercular activity of 
nicotinic and isoniazid analogues 
 Sephra.N.Rampersad et al., reported a Multiple applications of Alamar  Blue 
as an Indicator of Metabolic Function and cellular Health in Cell Viability 
Bioassays. 
 
Literature review for Spectroscopy    
 P.S.Kalsi wrote a book on Spectroscopy of Organic compounds. 
 
 D.Kealey et al., wrote a book on Instant notes Analytical chemistry.         
 
 Gurdeep R.Chatwal (2005) wrote a book on, Instrumental methods of 
chemical analysis. 
 
 Literature review on Schiff base  
 Denny.W.A et al., (1982) studied about the "Potential antitumor agents. 36. 
Quantitative relationships between experimental antitumor activity, toxicity, 
and structure for the general class of 9-anilinoacridine antitumor agents.  
 Rivera et al., (2007) studied the complexes of Pd(11)and Pt(11)with 9-amino 
acridine .reactions with DNA and study of their antiproliferative activity.  
 Tlegnov R.T (2008) studied the Condensation of 9-aminoacridine with p-
substituted aromatic aldehydes led to the synthesis of the corresponding 
azomethines  
 
N
N
R
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 Kylene kehn-Hall et al.,(2009) reported a 9-aminoacridine Inhibition of HIV-
1 Tat Dependent Transcription. 
 
 Sie-Tiong Ha1 et al.,( 2009) reported a Synthesis and Mesogenic Properties of 
New Schiff Bases Comprising Benzothiazole Moiety. 
 
 Ruby Naaz et al., (2010) reported a water mediated condensation reaction of 
aldehydes and amines. 
 
 
  
Gellerman Gary et al., (2010) "One-pot derivatization of medicinally 
important 9-aminoacridines by reductive amination and SNAr reaction"  
   N
NH
                                                  
 
 Yan-Hua Cai et al., (2010) reported a Synthesis of Schiff Base Derived from 
p-Aminobenzoic Acid by Solvent-Free Reaction Using Jet Milling. 
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 Shelar Mahendra Devidas et al., (2011) reported a Novel One-Pot Synthesis 
of Schiff Base Compounds Derived from Different Diamine & Aromatic 
Aldehyde Catalyzed by P2O5/SiO2 under Free-Solvent Condition at Room 
Temperature 
 
 M. M. Murhekar et al., (2011) Synthesis of Schiff bases by organic free 
solvent method. 
  
O
+
N
NH2
p2o5
sio2
N N
.  
 
 Eman Turky Shamkhy et al., (2011) reported a Preparation of New Schiff 
Base Derived from Cyclohexylamine with Piperonaldehyde and its Cu+2, 
Co+2 and Rh+3 Metal Complexes. 
 
 Muhammad Aqeel Ashraf, et al., (2011) reported a Synthesis, 
Characterization and Biological Activity of Schiff Bases  
 
 Tarek Aboul-Fadl et al., (2011) reported a Microwave-Assisted Solution-
Phase Synthesis and DART-Mass Spectrometric Monitoring of a 
combinatorial Library of Indolin-2, 3-dione Schiff Bases with Potential 
Antimycobacterial Activity. 
 
 John Maria Xavier et al., (2012) reported the Synthesis and spectral 
characterization of an aminoacetophenone-based Schiff base and its 
interaction studies with ascorbic acid. .    
 
 Savalia RV et al., (2013) reported a Rapid and Economic Synthesis of Schiff 
Base of Salicylaldehyde by Microwave Irradiation.  
AIM AND OBJECTIVE 
 
DEPARTMENT OF PHARMACEUTICAL CHEMISTRY  Page 23 
 
 
AIM & OBJECTIVE 
AIM 
To develop novel and potent methoxy mycolic acid (mmaa2) 1TPY inhibitors 
with anti- tubercular –activity. 
OBJECTIVE 
 Identification of the common Pharmacophore responsible for the inhibition of mmaa2 
using hip-hop molecule of catalyst software 4.11 from accelrys. 
 
 Using scaffold hopping technique, generation of 10,000 scaffolds from the drug. 
 
  Prediction of anti-tubercular activity for the designed using the hyporefine model   
and to identify novel and potent mmaa2 inhibitor using Lipinski rule of five. 
 
 The potent mmaa2 inhibitors attained as results can be used as lead for drug                       
development. 
 
 Docking of the lead with various derivatives using glide software to the target 1TPY. 
 
 The derivatives of the compounds from the lead molecule which has higher glide 
score value were synthesized. 
 
 Justification of the purity of synthesized compounds using the method of melting   
point,   thin layer chromatography. 
 
 Characterization of the synthesized compounds by using IR spectroscopy, MASS 
spectroscopy and NMR spectroscopy. 
 
 In vitro screening anti-tubercular activity of synthesized compounds. 
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 The present study carried out based on the below flow chart. 
      Obtain protein models from PDB              Structure of the ligand (DRAW-Chemsketch) 
 
Remove water/other hetero                      Generate mol file (convert into 3D) 
 
Remove other components                        Initial geometry refinement using molecular 
mechanics 
 
           Add hydrogens                                        Add hydrogens 
 
       Energy Minimisation                                Clean hybridizations 
         
        Define active site                      Final geometry optimization using quantum mechanics 
 
         Target molecule                                     Ligand molecules 
                                    
                                                   
 
                                                  Docking  
                                         
                                       Obtain binding energies 
                          
                                            Analysis 
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MATERIALS AND METHODS 
 
4.1) Drug design [20] 
A process of design and discovery of new chemical entities using an automated 
docking program GLIDE (grid based ligand docking with energetics) maestro 9.0 
Schrodinger suites. It searches molecules (ligands) having maximum favourable 
interactions with a receptor (target) usually a protein. Ligand is a single molecule 
whereas receptor may include proteins, metals and cofactors. It runs on rigid and 
flexible docking modes. The later generates conformations automatically for the input 
of each ligand and gives out the best fit pose of the molecule been docked on then 
receptor. The docking procedure involves protein preparation, ligand preparation, 
receptor grid generation and docking. 
A.Protein preparation [41]  
Protein preparation and refinement studies were performed on mmaA2. The protein 
was downloaded from the protein data bank with the following PDB ID: 1TPY, 
RESOLUTION 2.0A using protein preparation module (Schrodinger suite LLC) a 
typical PDB structure consists of heavy atoms, metal ions, cofactors, waters, etc. and 
can be multimeric. Protein preparation includes bond order adjustments, generating 
heterocyclic states, deleting water molecules except that co- ordinated to metals and 
waters which bridges ligand and protein are retained. Formal charges re-orient side 
chain hydroxyl groups and potential steric clashes via protein minimization with the 
OPLS-2005 force fields were assigned. 
                    Fig.5 
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B) Ligand preparation: 
Ligand preparation involves optimization of geometric parameters prior to docking 
.i.e. the compounds designed (structures) for docking should satisfy the following 
conditions. 
• It must be dimensional (3D). 
• IT must possess realistic bond lengths and bond angles. 
• It must possess each of a single molecule having no covalent bonds to the 
receptor, covalent bonds, counter ions and fragments. 
• It must possess all their hydrogens (filled vacancies). 
• It must possess an appropriate protonation state for physiological pH values. 
• The ligand preparation process comprises of a series of steps which 
includesation. 
• Conversions, applying corrections and generating variations to the structures, 
there by rendering optimization. 
C) Receptor grid generation: 
It involves generating a grid by representing the shape and properties of receptor 
using different tools of its wizard that progresses to the best fit pose of the ligand. 
This is done by defining the receptor structure by e excluding the crystal ligand 
already. The binding site in the grid was defined to a space of measuring 
10A*10A*10A*box on the centre of crystal inhibitor. Receptor grid determines the 
size and position of active site. Setting up of glide constraints like position or 
attachment of the crystal ligand, hydrogen bond interactions and locating the 
hydrophobic contacts. 
D) Docking procedure  
Docking was carried out by browsing the ligand grid base name and receptor grid 
base name files from their output files, which contains the 3D structures of the 
synthesised compounds and the receptor grid generated from the prepared protein has 
the 3D structure of mmaA2 enzyme respectively. The G score of the compounds were 
picturised in XP visualizer under glide software. 
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Flow chart showing design &docking; 
           
           Different conformations 
 
                 Fit optimization 
 
              Energy minimization 
 
             Interaction measured 
 
           Conformation fits the best 
 
ENZYME PROFILE [28] 
 
MmaA2 is required for introduction of the distal cyclopropane ring in the formation of 
meroacids. Analysis of a mmaA2 deletion mutant of M. tuberculosis revealed that 
mycolic acid lacks a distal cyclopropane group and instead contains a cis 
unsaturation. Thus, mmaA2 is required for the distal cyclopropane modification of _-
mycolic acid 
 
Functional category: lipid metabolism 
 
E) DOCKING SCORE METHOD: 
The compounds ranked by its G score which is the basic value obtained by the 
consideration of both rewards and penalties. Rewards- Lipophilic pair term and 
fraction of the total protein ligand vanderwaals energy, Hydrophobic enclosure 
reward, Hydrophobically packed Hydrogen bond, Hydrophobically packed correlated 
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hydrogen bond, hydrogen bond pair term, Electrostatic rewards, sitemap ligand/ 
receptor, pi and cation, chlorine and bromine, low molecular weight these all are basic 
parameters consider as rewards of the docking score. Rewards values are noted in 
negative values. 
Penalty- Ligand with large hydrophobic contacts and low Hydrogen bond scores, 
Exposed Hydrophobic ligand groups, Rotatable bond, similarity these are the basic 
penalty parameters of the docking score. The penalty values should be less in values 
to indicate best compound. (Table.1, 2) 
INTERACTIONS 
Binding mode of compound MI 3 and MI 4 in the active site of 1TPY dotted line 
indicates a hydrogen bond. 
Interaction between MI 3 and 1TPY Fig.6 
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Interaction between MI 4 and 1TPY Fig.7 
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4.1.2 LIPINSKI’S RULE [24] 
Lipinski's rule of five also known as the Pfizer's rule of five or simply the Rule of 
five (RO5) is a rule of thumb to evaluate drug likeness or determine if a chemical 
compound with a certain pharmacological or biological activity has properties that 
would make it a likely orally active drug in humans. The rule was formulated by 
Christopher A. Lipinski in 1997, based on the observation that most medication drugs 
are relatively small and lipophilic molecules. 
The rule describes molecular properties important for a drug's pharmacokinetics in the 
human body, including their absorption, distribution, metabolism, and excretion 
("ADME"). However, the rule does not predict if a compound is pharmacologically 
active. 
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The rule is important to keep in mind during drug discovery when a 
pharmacologically active lead structure is optimized step-wise to increase the activity 
and selectivity of the compound as well as to insure drug-like physicochemical 
properties are maintained as described by Lipinski's rule. Candidate drugs that 
conform to the RO5 tend to have lower attrition rates during clinical trials and hence 
have an increased chance of reaching the market. 
Lipinski’s rule says that, an orally active drug has no more than one violation of the 
following criteria; 
 1. Not more than 5 hydrogen bond donors (nitrogen or oxygen atoms with one or 
more hydrogen atoms) 
2. Not more than 10 hydrogen bond acceptors (nitrogen or oxygen atoms) 
3. A molecular weight under 500 Daltons. 
4. A partition coefficient log P less than 5. 
Lipinski’s Rule and Synthesized Compounds Table.3 
Compound 
ID 
nON nOHNH MilogP nrotb TPSA 
MOLECULAR 
FORMULA 
MOLECULAR 
WEIGHT 
Mi 3 2 0 5.131 2 25.256 C18H12N2S 288g/mol 
Mi 4 3 1 5.358 2 45.484 C20H13ClN2O 332g/mol 
 
Log P        -Partition coefficient 
TPSA         -Total Polar Surface Area 
NOHNH     -Number of hydrogen donors 
nON             -Number of hydrogen acceptors  
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4.1.3 Molinspiration  
 LogP (octanol/water partition coefficient) LogP is calculated by the methodology 
developed by Molinspiration as a sum of fragment based contributions and correction 
factors. Method is very robust and is able to process practically all organic and most 
organometallic molecules. 
 
Milog P 
Method for logP prediction developed at Molinspiration is based on group 
contributions. These have been obtained by fitting calculated logP with experimental 
logP for a training set more than twelve thousand, mostly drug-like molecules. 
 
Molecular property predictions using MolSoft 
In MolSoft all molecular property predictors are calculated using fragment-based 
contributions.  
 
Refractivity A3 
There are several potential classes of parameters used in QSAR studies. The selection 
of parameters is an important first step in any QSAR study. If the association between 
the parameter(s) than one of these rules may have problems with bioavailability. 
 
Nrotb-Number of Rotatable Bonds 
This simple topological parameter is a measure of molecular flexibility. It has been 
shown to be a very good descriptor of oral bioavailability of drugs.  
 
Molecular Polar Surface Area PSA 
Molecular polar surface area (PSA) is a very useful parameter for prediction of drug 
transport properties. 
 
Molecular volume 
Molecular volume determines transport characteristics of molecules, such as intestinal 
absorption or blood-brain barrier penetration. Volume is therefore often used in 
QSAR studies to model molecular properties and biological activity. 
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4.1.4 ADMET Properties Predictions [17, 33,] 
This was done using OSIRIS Property explorer which is an online tool. It lets one 
draw chemical structures and calculates on-the-fly various drug-relevant properties 
whenever a structure is valid. Properties with high risks of undesired effects like 
m1utagenicity or a poor intestinal  
Absorption is shown in red. Whereas a green colour indicates drug conform 
behaviour. It determines water solubility of a substance (log S). More than 80% of the 
drugs on the market have estimated log S value greater than -4. It determines partition 
coefficient of a substance (c log P). c Log P is the logarithm of a compound’s 
partition coeffient between n- octanol and water log (c octanol/c water). It has been 
shown for compounds to have a reasonable probability of being well absorbed their c 
log P value must not be greater than 5.0. Molecular weight, more than 80 % of all 
traded drugs have a molecular weight below 500 g/mol. Through this, the generated 
molecules were filtered out further by selecting only the molecules whose drug 
relevant properties conformed to those of most traded drugs.  
                                             OSIRIS RESULTS FOR MI 3 Fig.8 
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                                             OSIRIS RESULTS FOR MI 4 Fig.9 
 
 
Toxicity Assessment of Compounds by Osiris Property Explorer Table.4 
S.NO Properties MI 3 MI 4 
1 
 
Mutagenic 
Red Red 
2 
 
Tumorogenic 
Green Green 
3 
 
Irritant 
Green Green 
4 Reproductive Effect Green Green 
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4.2. SYNTHESIS 
Synthetic scheme was framed for the hit compounds from docking and the    
procedure for synthesis was collected from literatures. The necessary chemicals of 
laboratory grade for the synthesis were procured from Sigma Aldrich and Synthesis 
was carried out. 
4.2.1 REACTANT PROFILE [12] Table.5 
Structure Chemical Name 
Molecular 
Formula 
Formula 
Weight 
Density CAS. No 
S
O
H
 
thiophene-2-
carbaldehyde 
 
C5H4OS 112.1g/mol 1.2 98-03-3 
Cl
H
O
OH
 
5-chloro-2-
hydroxybenzaldeh
yde 
 
 
C7H5O2Cl 156.5g/mol 1.404 635-93-8 
 
Scheme: 1 [6, 25, 38] 
9 amino acridine and 2 Thiophene carboxaldehyde were weighed in the ratio of (1:1) 
and dissolved in methanol. The mixture was neutralised with sodium hydroxide. The 
pH was measure by pH paper .the reaction mixture was refluxed in a water bath for 3 
hours. The reaction mixture was cooled to room temperature. Again the reaction 
mixture was neutralised with dilute hydrochloric acid. The precipitate was formed 
after the neutralisation then the precipitate was filtered and recrystallized from 
ethanol. 
N
N H 2
+
a c rid in -9 -am in e
S
O
H
N
N
S
th iop h e ne -2 -ca rba ld e h yd e (E )-N -(a c r id in -9 -y l)-1 -(th io p he n -2 -y l)m e tha n im in e
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Scheme: 2 
9 amino acridine and 5 Chlorosalicyldehyde were weighed in the ratio of (1:1) and 
dissolved in methanol. The mixture was neutralised with sodium hydroxide. The pH 
was measure by pH paper .the reaction mixture was refluxed in a water bath for 3 
hours. The reaction mixture was cooled to room temperature. Again the reaction 
mixture was neutralised with dilute hydrochloric acid. The precipitate was formed 
then the neutralisation then the precipitate was filtered and recrystallized from 
ethanol.
N
NH2
+
acridin-9-amine
Cl
OH
H
O
N
N
Cl
OH
5-chloro-2-hydroxybenzaldehyde 2-[(E)-(acridin-9-ylimino)methyl]-4-chlorophenol
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4.2.2 RECRYSTALLISATION 
Ethanol was added to the synthesized compounds and heated until it dissolved 
completely. The clear solution thus obtained was filtered immediately and set aside 
for cooling .On cooling crystals gradually appeared. 
4.2.3 METHODS FOR IDENTIFICATION 
The synthesized compounds were identified by the following procedure, 
1) Determination of melting point 
2) Identification by TLC 
 
MELTING POINT: 
The melting points of the compounds were determined by capillary tube method. 
The temperature at which the synthesized compounds started losing its crystallinity 
and changing from solid to liquid form were found and recorded. Care was taken that 
the compound did not undergo decomposition during the progress. 
 
THIN LAYER CHROMATOGRAPHY 
Precoated silica gel aluminium plates were used as stationary phase. The products and 
the reactants were made into solution in suitable solvents and spotted on the TLC 
plate. Elution of the spot with different mobile phase was tried out of which benzene 
Chloroform and ethanol in the ratio 5:4:1 was selected as most preferred one. The RF 
values were calculated and found that reactants and product have different RF value 
which confirms that reactants have formed the product. 
 
Physical properties of the synthesized compounds and requirements and reaction 
conditions given the procedure. Products were obtained with a yield around 78% and 
then recrystallized. Then the physical properties such as appearance, solubility and 
melting point were determined and recorded. (Table.6) 
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4.2.4 CHARACTERIZATION [13, 18, 19] 
The synthesized compounds were characterized by Infrared spectra (IR), Nuclear 
Magnetic Resonance spectra (1H NMR), and Mass spectra (MS). 
 
INFRARED SPECTROSCOPY: 
Infrared spectroscopy serves as the tool to ascertain the presence and absence of the 
functional group. In this technique, Sample was made into pellet with potassium 
bromide using pellet press and then the pellet was mounted on the pellet disc. Then 
the percentage transmittance in the IR frequency region was measured by running the 
spectrophotometer and the spectrum obtained was interpreted to find the result. 
 
NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY: 
Proton NMR spectroscopy helps us to study the number of equivalent protons and 
their environment thereby we can ascertain the structure of the molecules. By running 
NMR spectrophotometer, Chemical shift will be produced based on the nature and 
environment of the proton and this chemical shift provides information on the 
structure of the molecule. Thereby the structure of the synthesized chemical 
compound was elucidated. Table: 6 Multiplicity and relative intensities of resonance 
Signals from coupled groups of nuclei in saturated structures Number of adjacent 
nuclei Multiplicity of observed resonance Relative intensity of components multiplets. 
Table.7 
Number of 
adjacent nuclei 
Multiplicity of 
observed resonance 
Relative intensity of 
components multiplets 
0 Singlet 1 
1 Doublet 1 1 
2 Triplet 1 2 1 
3 Quartet 1 3 3 1 
4 Quintet 1 4 6 4 1 
 
Chemical shift data give a general indication of the ranges in _/ppm within which the 
resonances for different types of structure or functional groups will occur. The 
chemical shift range for protons that can be involved in hydrogen bonding is 
particularly wide, as the variation in degree of shielding of these protons may be 
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highly concentration-dependent Peak areas are measured by electronic integration of 
the resonance signals in a spectrum. For proton spectra, the total area, or integral, of a 
multiplet is directly proportional to the number of protons in the group. Integrals are 
recorded as a series of steps, generally displayed above each resonance signal. The 
vertical height of each step, in arbitrary units, gives the relative number of protons 
associated with the signal. The interpretation of proton spectra depends on three 
features: chemical shifts, multiplicities of resonances and integrated peak areas.  
 
The following were the general approaches given to spectral interpretation, which was 
augmented by reference to chemical shift data, coupling constants and the spectra of 
known compounds. 
 Noted the presence or absence of saturated structures, which gives resonances 
between 0 and 5 (trichloromethane at 7.25 is a notable exception). 
 Noted the presence or absence of unsaturated structures in the region between about 5 
and 9 (alkene protons between 5 and 7 and aromatic protons between 7 and 9). 
(Alkyne protons are an exception, appearing at about 1.5). 
 Noted any very low field resonances (9 to 16) which are associated with Aldehyde 
and acidic protons, especially those involved in strong hydrogen bonding. 
 Measured the integrals and calculated the numbers of protons in each resonance 
signal. 
 Checked for spin-spin splitting patterns given by adjacent alkyl groups according to 
the n+1 rule and Pascal’s triangle. (N.B. The position of the lower field. 
 Multiplet of the two is very sensitive to the proximity of electronegative elements and 
groups such as O, CO, COO, OH, Cl, Br, NH2, etc.)  
 Examined the splitting pattern given by aromatic protons, which couple around the 
ring and are often complex due to second order effects.  
 1,4- and 1,2-disubstituted rings give complex but symmetrical looking patterns of 
peaks, whereas mono-, 1,3- and tri-substituted rings give more complex asymmetrical 
patterns 
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MASS SPECTROSCOPY: 
The synthesized compounds were analysed with Mass spectrometer, which enables us 
to establish the molecular structure and molecular weight of the compound. In this 
Technique, compound under investigation was bombarded with a beam of electron 
producing ionic fragments. The relative abundance of the fragment ion formed 
depends upon the stability of the ion and the lost radical. The resulting charged 
species travel at different speed and path based on their mass to charge ratio to reach 
the detector and the recorded spectrum will have molecular ion peak, base peak and 
isotope peak to interpret structure of the synthesized compound. 
 
Mass spectral data can be used to provide the following analytical information: 
• An accurate relative molecular mass if the molecular ion can be identified 
• An empirical molecular formula based on isotope peak intensities. 
 
The interpretation of molecular mass spectra is accomplished by comparisons with the 
spectra of known compounds and the application of a set of empirical rules. 
(i) The nitrogen rule states that compounds with an even-numbered relative 
Molecular mass must contain zero or an even number of nitrogen atoms, and those 
with an odd-numbered relative molecular mass must contain an odd number of 
nitrogen atoms. 
(ii) The unsaturated sites rule provides a means of calculating the number of 
Double-bond equivalents in a molecule from the formula 
No. of C atoms + 1⁄2 (no. of N atoms) - 1⁄2 (no. of H + halogen atoms) + 1 
(iii) Double bonds and cyclic structures tend to stabilize the molecular ion, saturated 
rings losing side chains at the a-position. 
(iv) Alkyl-substituted aromatic rings cleave at the b-bond to the ring giving a 
prominent peak at m/z 91, which corresponds to the tropylium ion, C7H7+. 
(v) Small neutral molecules, such as CO, C2H4, C2H2, H2O and NH3 are often lost 
during fragmentation. 
(vi) The C-C bond adjacent to a heteroatom (N, O, S) is frequently cleaved leaving 
The charge on the fragment containing the heteroatom, whose nonbonding electrons 
Provide resonance stabilization. 
(vii) McLafferty rearrangements in carbonyl compounds are common.  
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IR Spectrum of MI3 Fig.10 
 
 
Table.8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
COMPOUND NAME IR REGION cm-1 
MI3 
3039 (Ar C-H) 
1643 (C=N) 
1596(C=C) 
756 (C-S) 
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NMR Spectrum of MI3 Fig.11 
 
 
Table.9 
 
COMPOUND NAME 1H NMR Data 
MI3 
9 8.62-8.7 (d, 3H, Ar-H). 
7.88-7.99 (M, 5H, Ar-H). 
7.42-7.56 (M, 3H, Ar-H). 
2.46-2.63 (S, 1H, -CH). 
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MASS Spectrum MI3 Fig.12 
 
 
 
Table.10 
 
COMPOUND 
NAME 
Mol. for/ Mol Wt. 
(calculated) 
m/e value 
(Relative abundance) 
MI3 C18H12N2S /288 
289 (M+) 
244 (B) 
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IR spectrum of MI4 Fig.13 
 
 
Table.11 
COMPOUND NAME IR REGION cm-1 
MI4 
3232 (Ar O-H) 
3039 (Ar C-H) 
1643 (C=N) 
1596(C=C) 
750 (C-Cl) 
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NMR Spectrum of MI4  Fig.14 
 
 
 
 
Table.12 
COMPOUND NAME 1H NMR Data 
MI 4 
10.1-10.4 (S, 1H, OH) 
8.3-8.7 (d, 2, Ar-H) 
7.6-7.9 (m, 4H, Ar-H) 
7.2-7.5 (m, 4H, Ar-H) 
6.8-7.1 (d, 1H, Ar-H) 
2.3-2.6 (S, 1H, CH) 
 
 
 
 
MATERIALS AND METHOD 
 
DEPARTMENT OF PHARMACEUTICAL CHEMISTRY Page 46 
 
MASS Spectrum of MI4 Fig.15 
 
 
Table.13 
COMPOUND 
NAME 
Mol. for/ Mol Wt. 
(calculated) m/e value (Relative abundance) 
MI4 C20H13N2OCl / 332 
333 (M+) 
238 (B) 
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4.3) BIOLOGICAL SCREENING 
4.3.1ANTI- TUBERCULAR ACTIVITY   [4, 27, 34,] 
As discussed, from earlier to the present status, tuberculosis is existing with (extreme 
&multi-drug resistance), increased susceptibility in transmission, their complex 
pathophysiology leading to higher risks of infections to other organs and increases the 
rate of mortality.so essentially there is an urgent and rapid need of drugs to combat 
this disease, which in turn it is screened for anti-tuberculosis activity. 
There are various high through put assays are available for screening of new chemical 
entities against tuberculosis of which ,we have chosen MABA assay and the rest of us 
are enlisted below. 
• Micro plate Alamar blue assay (MABA) 
• BACTEC assay 
• Lactiferous reporter phage assay (LRP) 
• REMA assay 
• Broth dilution assay 
• Middle brook (7H 9, 7H 10, 7H 11,) Agar dilution assay 
Principle 
 The micro plate Alomar blue assay (MABA) is an indirect colorimetric DST method 
for determining the MICs of TB drugs for strains of mycobacterium tuberculosis .in 
this assay, the redox indicator Alomar blue monitors the reducing environment of the 
living cell.it turns from blue to pink in the presence of mycobacterial growth. 
Procedure  
The anti- mycobacterial activity of compounds (MI3, MI4 ) were assessed against 
M.tuberculosis using micro plate Almar blue assay (MABA)  
This methodology is non –toxic, uses a thermally stable reagent and shows good 
correlation with proportional and BACTEC radiometric method. 
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Briefly, 200ml of sterile de-ionized water was added to all outer perimeter wells of 
sterile 96 wells plate to minimized evaporation of medium in the test wells during 
incubation. 
The 96 wells plate received 100ml of the middle brook 7H9 broth and serial dilution 
of compounds was made directly on plate. 
The final drug concentrations tested were 100 to 0.8mg/ml 
Plates were covered and sealed with parafilm and incubated at 37c for dive days. 
After this time 25ml of freshly prepared 1; 1   mixture of almar blue reagent and 10% 
tween 80 was added to the plate and incubated for 24 hours. 
A blue colour in the well was interpreted as no bacterial growth, and pink colour was 
scored as growth. 
The MIC was defined as lowest drug concentration which prevented the colour 
change from blue to pink. 
Advantages: 
• It has accurate time –course measurements, 
• It has high sensitivity and linearity, 
• It involves no cell lies, 
• It  involves  no cell lysis, 
• It is ideal for use with post –measurement functional assays, 
• It is flexible as it can be used with different cell models, 
• It is scable and can be used with fluorescence- and/or absorbance –based 
instrumentation platforms, 
• Finally ,it is non-toxic, on –radioactive and is safe for the user 
• Application  
• Especially meant for studies on mycobacterium tuberculosis 
• Used extensively in cell viability and cytotoxicity studies 
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Other applications  
• Exploited for monitoring immune cell proliferation and function. 
• Useful in identifying resistance-compromised mutants and identification of 
compounds with anti-biofilm activity. 
• Recently, the Almar Blue assay has been used to study fungicide sensitivity of five 
plant pathogens, Monilina fructicola, Botrytis cinera, Verticullium dahlia, 
Colletotrichum spp.and Alternaria alternate. 
• Alamar Blue assay to evaluate plant cell viability and /or proliferation in tomato 
cell suspension was studied 
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RESULT AND DISCUSSION 
5.1 DRUG DESIGN   
5.1.1 Glide Docking 
A promising heterocyclic nucleus Schiff base Which was Prominently proved of 
exhibiting different biological activities had been used to prepare a database which was 
then docked against 1 TPY protein for Antitubercular activity.by using Glide Software  
( Maestro 9.1) Compound MI 4gave favourable interaction with the active site amino 
acids Gly 203 and Phe 200 
Extra Precision (XP) scoring function was utilised to rank order compounds. The 
different derivatives of Schiff base were docked to the specific protein target site. The 
best compounds with top scored were filtered. Top scored compounds were selected 
and synthesized. 
5.1.2 Lipinski Rule and Toxicity Risk Assessment 
All the compounds pass the Lipinski rule there is no violation in the basic properties 
and the ADME/Toxicity profile were studied. It’s proves that our molecule has ability 
to reach the target site for the action. 
5.2 SYNTHESIS &CHARACTERIZATION 
5.2.1 Synthesis  
The compound mi 3-mi 4 prepared by the condensation of primary amine with aromatic 
aldehyde  
5.2.2 Characterization 
The synthesized compounds were recrystallized and the reaction was monitored by 
TLC. The melting point of the products were found and are presented uncorrected. The 
characterization was carried out using sophisticated instruments like, IR, NMR, and 
MASS Spectroscopy. 
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The results are shown below: 
IR SPECTROSCOPY 
The IR Spectroscopy has been used to identify the synthesized compounds. The 
presence of impurities like starting raw material i.e. aldehyde, amine were ruled out by 
ensuring absence of the functional group of the parent compounds.  
The synthesized compounds show the following specific characteristics stretching 
vibrations. 
Compound MI 3 
3039cm
-1
- Aromatic C-H Stretching 
1643 cm
-1
 – C=N Stretching 
1596 cm
-1 
-C=C Stretching 
756 cm
-1 
- C-S Stretching 
Compound MI 4 
3232cm
-1
- Aromatic O-H Stretching 
3039cm
-1
- Aromatic C-H Stretching  
1643cm
-1
 – C=N Stretching 
1596cm
-1
-C=C Stretching 
750cm
-1
 - C-Cl Stretching 
The presence of the Schiff base functional and the absence of reactant functional groups 
confirmed our compound has formed. 
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NMR SPECTROSCOPY 
The H1 NMR Spectral data of all the synthesized compounds were in conformity with 
the structural assigned. The H1NMR Spectral data of all the synthesized compounds 
were in conformity with the structure assigned. A short sharp singlet was observed at 
4.9- 5.0 for all compounds which might be due to the presence of NH proton. 
Compound MI 3 
9 8.62-8.7 (d, 3H, Ar-H). 
7.88-7.99 (M, 5H, Ar-H). 
7.42-7.56 (M, 3H, Ar-H). 
2.46-2.63 (S, 1H, -CH). 
Compound MI 4 
10.1-10.4 (S, 1H, OH) 
8.3-8.7 (d, 2, Ar-H) 
7.6-7.9 (M, 4H, Ar-H) 
7.2-7.5 (M, 4H, Ar-H) 
6.8-7.1 (d, 1H, Ar-H) 
2.3-2.6 (S, 1H, CH) 
MASS SPECTROSCOPY 
All the synthesized compounds exhibited molecular ion peak (M
+
) of varying 
intensities ascertaining the molecular weights of the compounds. It was observed that 
the compounds. It was observed that the compounds MI 3, MI 4 gave fragment ions at 
m/e ratio values 289, 333. 
All the above spectral data confirmed that assigned structure of synthesized 
compounds. 
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5.3 BIOLOGICAL SCREENING 
Antitubercular Screening 
The antimycobacterial activities of the synthesized compounds were determined by 
MABA method. The organism used in this study is M.tuberculosis H37Rv. 
All the synthesised compounds showed antibacterial activity to varying degree against 
the organism tested. The pathogen tested was susceptible to all the synthesized 
compounds but the minimum inhibitory concentration(MIC) for the compounds varied 
between 100 to 0.2 µg/lathe data pertaining to these observations are presented in  no. 
and the growth of organisms is shown in Fig no. It was observed from the study that 
minimum inhibitory concentration of the synthesized showed good antimycobacterial 
activity. Inhibition was compared using standard pyrazinamide 3.125µg/ml 
ciprofloxacin 3.125µg/ml, and streptomycin 6.25 µg/ml as standard. 
Among the synthesized compounds  MI 2, MI 5 show good activity at minimum 
concentration 3.12 µg/ml. Compounds MI 1,MI 3,MI 4, exhibit moderate activity 
minimum inhibition at  6.25 2 µg/ml. 
         5.3.1 Anti-TB activity using Almar Blue Dye 
1) The anti-mycobacterial activity of compounds were assessed against M. tuberculosis 
using micro plate Almar Blue assay (MABA). 
2) This methodology is non-toxic, uses a thermally stable reagent and shows good 
correlation with proportional and BACTEC radiometric method. 
3) Briefly, 200µl of sterile deionized water was added to all outer perimeter wells of 
sterile 96 wells plate to minimized evaporation of medium in the test wells during 
incubation. 
4) The 96 wells plate received 100 µl of the Middle brook 7H9 broth and serial dilution of 
compounds was made directly on plate. 
5) The final drug concentrations tested were 100 to 0.2 µg/ml. 
6) Plates were covered and sealed with parafilm and incubated at 37ºC for five days. 
7) After this time, 25µl of freshly prepared 1:1 mixture of Almar Blue reagent and 10% 
tween 80 was added to the plate and incubated for 24 hrs.  
RESULT & DISCUSSION 
 
PHARMACEUTICAL CHEMISTRY Page 54 
 
8) A blue colour in the well was interpreted as no bacterial growth, and pink colour was 
scored as growth.  
9) The MIC was defined as lowest drug concentration which prevented the colour change 
from blue to pink. 
      
Inhibition of synthesized compounds against Mycobacterium Tuberculosis at Lowest 
concentration. 
 
Fig.16 
 
 
Organism - M.tuberculosis H37Rv 
B-Blue indicates sensitive (S) 
P-Pink indicates resistant (R) 
 
 
Table.14 
 
 
 
 
SI. No Samples 
100 
µg/ml 
50 
µg/ml 
25 
µg/ml 
12.5 
µg/ml 
6.25 
µg/ml 
3.12 
µg/ml 
1.6 
µg/ml 
0.8 
µg/ml 
1 MI3 S S S S S R R R 
2 MI4 S S S S S R R R 
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ANALYSIS OF G SCORE VS ACTIVITY OF SYNTHESISED MOLECULES 
Table.15 
 
ANALYSIS OF G SCORE VS ACTIVITY OF STANDARD MOLECULES 
Table.16 
SI NO COMPOUND ID G SCORE ACTIVITY 
1 Ciprofloxacin -7.5 3.15 
2 Pyrazinamide -5.8 3.15 
3 Streptomycin -4.9 6.25 
  
    
.  
SI NO COMPOUND ID G SCORE ACTIVITY 
1 MI 4 -8.86 6.25 
3 MI 3 -8.66 6.25 
SUMMARY AND CONCLUSION 
 
DEPARTMENT OF PHARMACEUTICAL CHEMISTRY Page 56 
 
SUMMARY AND CONCLUSION 
 
1. 1TPY a critical enzyme for the growth of Mycobacterium tuberculosis was 
chosen for our study after review of literature. 
 
2. A database of 50 molecules with high prospect of inhibiting the target 1TPY were 
carefully chosen by making changes into the known hit molecule, here the 
acridine nucleus. 
 
3. Candidate molecules were designed and docked against 1TPY protein using 
Glide® (grid based ligand docking with energetics) program. 
 
4. Two molecules with good G-Score (high stablility/lower binding energy ) were 
shortlisted for the synthesis . They were labelled as MI3, and MI4 
 
5. Two compounds were synthesized with good yield by conventional Schiff base 
reaction involving condensation between the 9-Amino Acridine and different 
types of aromatic aldehydes. 
 
6. The purity of the synthesized compounds were evaluated by melting point, TLC, 
recrystallization. 
 
7. The synthesized compounds were characterized by IR spectroscopy, NMR 
spectroscopy and Mass spectroscopy. 
 
8. The pure compounds were screened for In-vitro Anti-tubercular activity by 
Microplate Alamar Blue Assay (MABA) method. 
9. Two compounds showed significant invitro antitubercular activity. The 
compounds MI3, MI4, showed minimum inhibitory concentration at 6.25mg/ml 
against the MIC of standard drugs Pyrazinamide: 3.125mcg/ml, Ciprofloxacin: 
3.125 mcg/ml, Streptomycin: 6.25 mcg/ml. 
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Conclusion: 
      The G-Score of the synthesized compounds ranged between -8.86 to -8.66.  
The docking scores of Standard drugs against 1TPY were  
Pyrazinamide: -5.8 kcal/mol, 
Ciprofloxacin: -7.5 kcal/mol, 
Streptomycin: -4.9 kcal/mol. 
So there is correlation between the docking study and In-vitro Antimycobacterial 
activity.   The results of our study conclude that 1TPY is a critical enzyme for 
Antimycobacterial activity. These compounds can be attractive starting point to 
find newer molecules by fine tuning the structures to yield compounds with better 
activity against Mycobacterium tuberculosis. 
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